Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Immunotherapy for Resectable Pancreatic Cancer
NCT02451982Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2016
- Primary completion
- Dec 2026
- Modality
- Cell Therapies, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GVAX pancreatic cancer vaccine, nivolumab, urelumab, adakitug in pancreatic cancer (PC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2016; status: active, not recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02451982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451982.